proxalutamide developmental code name nonsteroidal antiandrogen nsaa specifically selective highaffinity silent antagonist androgen receptor ar development suzhou kintor pharmaceuticals inc subsidiary kintor pharmaceutical limited potential treatment prostate cancer breast approved paraguay treatment july approved time proxalutamide phase iii studies mcrpc monotherapy combination abiraterone united states phase ii study monotherapy proxalutamide phase ic clinical trial antineoplastic immunomodulatory drug article stub help wikipedia expanding httpsenwikipediaorgwikiproxalutamide